# OnCo record hd21 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/hd21/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "hd21", "NCT02661503" ;
  schema:name "GHSG HD21"@en ;
  schema:description "A new brentuximab-based intensive regimen matched Europe's most effective (and most toxic) chemotherapy with far fewer side effects."@en ;
  schema:url <https://onco.cc/trials/hd21/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02661503> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2016-07" ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/trials/hd18/>, <https://onco.cc/trials/ahl2011/>, <https://onco.cc/trials/hd10/> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/pet-adapted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:companies <https://onco.cc/companies/gbg/>, <https://onco.cc/companies/ghsg/> ;
  onco:people <https://onco.cc/people/peter-borchmann/> .